Browse by Phase
Phase 1 / Phase 2 Clinical Trials
Phase 1/2 combined trials evaluate both safety (Phase 1) and preliminary efficacy (Phase 2) in a single study protocol, often used to accelerate early development.
Total Trials
384
Recruiting Now
384
Top Conditions in Phase 1 / Phase 2
Frequently Asked Questions — Phase 1 / Phase 2 Trials
What are combined Phase 1/2 clinical trials?
Phase 1/2 trials are adaptive designs that evaluate both safety (Phase 1 objectives) and preliminary efficacy (Phase 2 objectives) within a single trial protocol. They are commonly used in oncology and rare disease research to accelerate development timelines. Dose escalation occurs in the Phase 1 portion, followed by expansion cohorts at the selected dose in the Phase 2 portion.
Why do sponsors combine Phase 1 and Phase 2?
Combining phases reduces development time and cost, particularly for conditions with high unmet need. For rare diseases or cancer indications, finding sufficient eligible patients can be challenging—a combined design uses the same patient pool more efficiently. Regulatory agencies including the FDA encourage adaptive designs to accelerate evidence generation for serious conditions.
How do I find Phase 1/2 trials I can join?
Phase 1/2 trials listed on ClinicalMetric are sourced from ClinicalTrials.gov and filtered by recruitment status. Each listing shows enrollment status, conditions studied, sponsor, participating sites, and estimated enrollment. Because Phase 1/2 trials often have narrow eligibility criteria, carefully review the protocol and discuss potential participation with your treating physician.
Active Phase 1 / Phase 2 Studies
NCT06937866 Phase 1, Phase 2
Recruiting
Maintenance Zanzalintinib With Etoposide After HDCT in GCT
Condition
Germ Cell Tumor
Enrollment
38 pts
Location
United States
Sponsor
Indiana University
NCT06839456 Phase 1, Phase 2
Recruiting
Phase 1/2: CD45RA Depleted Stem Cell Addback to Prevent Viral or Fungal Infectio...
Condition
Leukemia
Enrollment
100 pts
Location
United States
Sponsor
Children's Hospital of Philade
NCT07630974 Phase 1, Phase 2
Recruiting
A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refr...
Condition
Malignant Neoplasm
Enrollment
134 pts
Location
United States, Australia, Belgium
Sponsor
Merck Sharp & Dohme LLC
NCT05867420 Phase 1, Phase 2
Recruiting
A Study of ASKG915 in Patients With Selected Advanced Solid Tumors.
Condition
Advanced Solid Tumors
Enrollment
594 pts
Location
United States, China
Sponsor
AskGene Pharma, Inc.
NCT03686124 Phase 1, Phase 2
Recruiting
ACTengine® IMA203/IMA203CD8 as Monotherapy or in Combination With Nivolumab in R...
Condition
Refractory Cancer
Enrollment
375 pts
Location
United States, Germany
Sponsor
Immatics US, Inc.
NCT07471789 Phase 1, Phase 2
Recruiting
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid...
Condition
Acute Myeloblastic Leukaemia
Enrollment
33 pts
Location
Spain
Sponsor
Gyala Therapeutics
NCT06975618 Phase 1, Phase 2
Recruiting
Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Eff...
Condition
PIK3CA-Related Overgrowth Spectrum (PROS)
Enrollment
141 pts
Location
China, Japan
Sponsor
Haihe Biopharma Co., Ltd.
NCT04086290 Phase 1, Phase 2
Recruiting
National Danish Protocol. Surgery+ SBRT for M1 Prostate Cancer Patients
Condition
Prostate Cancer Metastatic
Enrollment
20 pts
Location
Denmark
Sponsor
Peter Busch Østergren
NCT07093710 Phase 1, Phase 2
Recruiting
Golidocitinib Combined With Mitoxantrone Hydrochloride Liposome or Chidamide in ...
Condition
Peripheral T Cell Lymphoma
Enrollment
101 pts
Location
China
Sponsor
Sun Yat-sen University
NCT05761223 Phase 1, Phase 2
Recruiting
A Phase I/II, Open-label Study to Investigate the Safety, Tolerability, PK, and ...
Condition
Advanced Solid Tumor
Enrollment
151 pts
Location
United States
Sponsor
1ST Biotherapeutics, Inc.
NCT07164976 Phase 1, Phase 2
Recruiting
Ribociclib for HR-positive HER2-negative Metastatic Breast Cancer
Condition
Breast Cancer
Enrollment
86 pts
Location
Japan
Sponsor
Nagoya City University
NCT05842174 Phase 1, Phase 2
Recruiting
Targeting Ischemia-Induced Autophagy Dependence in Hepatocellular Carcinoma
Condition
Hepatocellular Carcinoma
Enrollment
93 pts
Location
United States
Sponsor
VA Office of Research and Deve
NCT05123482 Phase 1, Phase 2
Recruiting
A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Adv...
Condition
Breast Cancer
Enrollment
460 pts
Location
United States, Australia, Belgium
Sponsor
AstraZeneca
NCT07482059 Phase 1, Phase 2
Recruiting
A Multicenter Clinical Study of Combined Therapy for Unresectable Hepatocellular...
Condition
Unresectable Hepatocellular Carcinoma
Enrollment
33 pts
Location
China
Sponsor
West China Hospital
NCT07681596 Phase 1, Phase 2
Recruiting
A Modular, Phase I/II, Multicentre Study to Evaluate AZD4045, in Participants Wi...
Condition
Relapsed or Refractory Multiple Myeloma
Enrollment
101 pts
Location
United States, Australia
Sponsor
AstraZeneca
NCT03850574 Phase 1, Phase 2
Recruiting
Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharma...
Condition
Leukemia, Myeloid, Acute
Enrollment
240 pts
Location
United States, Australia, Germany
Sponsor
Aptose Biosciences Inc.
NCT07416188 Phase 1, Phase 2
Recruiting
Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Gl...
Condition
Recurrent Glioblastoma
Enrollment
40 pts
Location
United States
Sponsor
National Institute of Neurolog
NCT07735104 Phase 1, Phase 2
Recruiting
The First in Human Study of QLS2319 in Healthy Subjects and Cancer Cachexia
Condition
Cancer Cachexia
Enrollment
88 pts
Location
China
Sponsor
Qilu Pharmaceutical Co., Ltd.
NCT07529808 Phase 1, Phase 2
Recruiting
Phase 1/2 Study of BHB810 in Advanced Gastric and GEJ Adenocarcinoma
Condition
Gastric Cancer
Enrollment
164 pts
Location
United States
Sponsor
BigHat Biosciences, Inc.
NCT07108855 Phase 1, Phase 2
Recruiting
Detection of Upper Gastrointestinal Tumour Depth and Demarcation Using Systemic ...
Condition
Esophageal Carcinoma
Enrollment
10 pts
Location
Netherlands
Sponsor
University Medical Center Gron
NCT07399626 Phase 1, Phase 2
Recruiting
Adaptation and Validation of the Hypomanic Personality Scale (HPS-6) to Romanian
Condition
Bipolar Disorder (BD)
Enrollment
50 pts
Location
Romania
Sponsor
Babes-Bolyai University
NCT05868226 Phase 1, Phase 2
Recruiting
PRE-ISPY Phase I/II Oncology Platform Program
Condition
HER2-positive Breast Cancer
Enrollment
280 pts
Location
United States
Sponsor
QuantumLeap Healthcare Collabo
NCT04590326 Phase 1, Phase 2
Recruiting
A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women Wh...
Condition
Ovarian Cancer
Enrollment
612 pts
Location
United States, Belgium, Brazil
Sponsor
Regeneron Pharmaceuticals
NCT07843940 Phase 1, Phase 2
Recruiting
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced...
Condition
Extensive-stage Small Cell Lung Carcinoma
Enrollment
55 pts
Location
United States, Australia, Belgium
Sponsor
Boehringer Ingelheim
NCT05590689 Phase 1, Phase 2
Recruiting
Radiodynamic Therapy (RDT) With Gliolan in Patients With First Recurrence of Bra...
Condition
Glioblastoma
Enrollment
34 pts
Location
Germany
Sponsor
Universität Münster
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: November 2026 · Data Methodology